Neoantigen Cancer Vaccine Market Analysis, Size, Report to 2033

Market Segmentation

Neoantigen Cancer Vaccine Market, By Product (2021-2033)

Personalised neo-antigen vaccine
Off-the-shelf neoantigen vaccine

Neoantigen Cancer Vaccine Market, By Neoantigen Type (2021-2033)

Synthetic Long Peptide
Nucleic acid
Dendritic cell
Tumour cell

Neoantigen Cancer Vaccine Market, By Route of Administration (2021-2033)

Intravenous
Intramuscular
Transdermal
Others

Neoantigen Cancer Vaccine Market, By Cell (2021-2033)

Autologous
Allogenic

Neoantigen Cancer Vaccine Market, By Technology (2021-2033)

RNA Sequencing
Whole Genome Sequencing
HLA Typing

Neoantigen Cancer Vaccine Market, By Delivery Mechanism (2021-2033)

Liposomes
Virosomes
Gene gun
Electroporation
Others

Neoantigen Cancer Vaccine Market, By Application (2021-2033)

Lung
Melanoma
Gastrointestinal
Brain cancer
Others

Regional Neoantigen Cancer Vaccine Market

North America
1. North America Neoantigen Cancer Vaccine Market, By Product
  1. Personalised neo-antigen vaccine
  2. Off-the-shelf neoantigen vaccine
2. North America Neoantigen Cancer Vaccine Market, By Neoantigen Type
  1. Synthetic Long Peptide
  2. Nucleic acid
  3. Dendritic cell
  4. Tumour cell
3. North America Neoantigen Cancer Vaccine Market, By Route of Administration
  1. Intravenous
  2. Intramuscular
  3. Transdermal
  4. Others
4. North America Neoantigen Cancer Vaccine Market, By Cell
  1. Autologous
  2. Allogenic
5. North America Neoantigen Cancer Vaccine Market, By Technology
  1. RNA Sequencing
  2. Whole Genome Sequencing
  3. HLA Typing
6. North America Neoantigen Cancer Vaccine Market, By Delivery Mechanism
  1. Liposomes
  2. Virosomes
  3. Gene gun
  4. Electroporation
  5. Others
7. North America Neoantigen Cancer Vaccine Market, By Application
  1. Lung
  2. Melanoma
  3. Gastrointestinal
  4. Brain cancer
  5. Others
8. U.S.
  1. U.S. Neoantigen Cancer Vaccine Market, By Product
    1. Personalised neo-antigen vaccine
    2. Off-the-shelf neoantigen vaccine
  2. U.S. Neoantigen Cancer Vaccine Market, By Neoantigen Type
    1. Synthetic Long Peptide
    2. Nucleic acid
    3. Dendritic cell
    4. Tumour cell
  3. U.S. Neoantigen Cancer Vaccine Market, By Route of Administration
    1. Intravenous
    2. Intramuscular
    3. Transdermal
    4. Others
  4. U.S. Neoantigen Cancer Vaccine Market, By Cell
    1. Autologous
    2. Allogenic
  5. U.S. Neoantigen Cancer Vaccine Market, By Technology
    1. RNA Sequencing
    2. Whole Genome Sequencing
    3. HLA Typing
  6. U.S. Neoantigen Cancer Vaccine Market, By Delivery Mechanism
    1. Liposomes
    2. Virosomes
    3. Gene gun
    4. Electroporation
    5. Others
  7. U.S. Neoantigen Cancer Vaccine Market, By Application
    1. Lung
    2. Melanoma
    3. Gastrointestinal
    4. Brain cancer
    5. Others
9. Canada
Europe
1. Europe Neoantigen Cancer Vaccine Market, By Product
  1. Personalised neo-antigen vaccine
  2. Off-the-shelf neoantigen vaccine
2. Europe Neoantigen Cancer Vaccine Market, By Neoantigen Type
  1. Synthetic Long Peptide
  2. Nucleic acid
  3. Dendritic cell
  4. Tumour cell
3. Europe Neoantigen Cancer Vaccine Market, By Route of Administration
  1. Intravenous
  2. Intramuscular
  3. Transdermal
  4. Others
4. Europe Neoantigen Cancer Vaccine Market, By Cell
  1. Autologous
  2. Allogenic
5. Europe Neoantigen Cancer Vaccine Market, By Technology
  1. RNA Sequencing
  2. Whole Genome Sequencing
  3. HLA Typing
6. Europe Neoantigen Cancer Vaccine Market, By Delivery Mechanism
  1. Liposomes
  2. Virosomes
  3. Gene gun
  4. Electroporation
  5. Others
7. Europe Neoantigen Cancer Vaccine Market, By Application
  1. Lung
  2. Melanoma
  3. Gastrointestinal
  4. Brain cancer
  5. Others
8. U.K.
  1. U.K. Neoantigen Cancer Vaccine Market, By Product
    1. Personalised neo-antigen vaccine
    2. Off-the-shelf neoantigen vaccine
  2. U.K. Neoantigen Cancer Vaccine Market, By Neoantigen Type
    1. Synthetic Long Peptide
    2. Nucleic acid
    3. Dendritic cell
    4. Tumour cell
  3. U.K. Neoantigen Cancer Vaccine Market, By Route of Administration
    1. Intravenous
    2. Intramuscular
    3. Transdermal
    4. Others
  4. U.K. Neoantigen Cancer Vaccine Market, By Cell
    1. Autologous
    2. Allogenic
  5. U.K. Neoantigen Cancer Vaccine Market, By Technology
    1. RNA Sequencing
    2. Whole Genome Sequencing
    3. HLA Typing
  6. U.K. Neoantigen Cancer Vaccine Market, By Delivery Mechanism
    1. Liposomes
    2. Virosomes
    3. Gene gun
    4. Electroporation
    5. Others
  7. U.K. Neoantigen Cancer Vaccine Market, By Application
    1. Lung
    2. Melanoma
    3. Gastrointestinal
    4. Brain cancer
    5. Others
9. Germany
10. France
11. Spain
12. Italy
13. Russia
14. Nordic
15. Benelux
16. Rest of Europe
APAC
1. APAC Neoantigen Cancer Vaccine Market, By Product
  1. Personalised neo-antigen vaccine
  2. Off-the-shelf neoantigen vaccine
2. APAC Neoantigen Cancer Vaccine Market, By Neoantigen Type
  1. Synthetic Long Peptide
  2. Nucleic acid
  3. Dendritic cell
  4. Tumour cell
3. APAC Neoantigen Cancer Vaccine Market, By Route of Administration
  1. Intravenous
  2. Intramuscular
  3. Transdermal
  4. Others
4. APAC Neoantigen Cancer Vaccine Market, By Cell
  1. Autologous
  2. Allogenic
5. APAC Neoantigen Cancer Vaccine Market, By Technology
  1. RNA Sequencing
  2. Whole Genome Sequencing
  3. HLA Typing
6. APAC Neoantigen Cancer Vaccine Market, By Delivery Mechanism
  1. Liposomes
  2. Virosomes
  3. Gene gun
  4. Electroporation
  5. Others
7. APAC Neoantigen Cancer Vaccine Market, By Application
  1. Lung
  2. Melanoma
  3. Gastrointestinal
  4. Brain cancer
  5. Others
8. China
  1. China Neoantigen Cancer Vaccine Market, By Product
    1. Personalised neo-antigen vaccine
    2. Off-the-shelf neoantigen vaccine
  2. China Neoantigen Cancer Vaccine Market, By Neoantigen Type
    1. Synthetic Long Peptide
    2. Nucleic acid
    3. Dendritic cell
    4. Tumour cell
  3. China Neoantigen Cancer Vaccine Market, By Route of Administration
    1. Intravenous
    2. Intramuscular
    3. Transdermal
    4. Others
  4. China Neoantigen Cancer Vaccine Market, By Cell
    1. Autologous
    2. Allogenic
  5. China Neoantigen Cancer Vaccine Market, By Technology
    1. RNA Sequencing
    2. Whole Genome Sequencing
    3. HLA Typing
  6. China Neoantigen Cancer Vaccine Market, By Delivery Mechanism
    1. Liposomes
    2. Virosomes
    3. Gene gun
    4. Electroporation
    5. Others
  7. China Neoantigen Cancer Vaccine Market, By Application
    1. Lung
    2. Melanoma
    3. Gastrointestinal
    4. Brain cancer
    5. Others
9. Korea
10. Japan
11. India
12. Australia
13. Taiwan
14. South East Asia
15. Rest of Asia-Pacific
Middle East and Africa
1. Middle East and Africa Neoantigen Cancer Vaccine Market, By Product
  1. Personalised neo-antigen vaccine
  2. Off-the-shelf neoantigen vaccine
2. Middle East and Africa Neoantigen Cancer Vaccine Market, By Neoantigen Type
  1. Synthetic Long Peptide
  2. Nucleic acid
  3. Dendritic cell
  4. Tumour cell
3. Middle East and Africa Neoantigen Cancer Vaccine Market, By Route of Administration
  1. Intravenous
  2. Intramuscular
  3. Transdermal
  4. Others
4. Middle East and Africa Neoantigen Cancer Vaccine Market, By Cell
  1. Autologous
  2. Allogenic
5. Middle East and Africa Neoantigen Cancer Vaccine Market, By Technology
  1. RNA Sequencing
  2. Whole Genome Sequencing
  3. HLA Typing
6. Middle East and Africa Neoantigen Cancer Vaccine Market, By Delivery Mechanism
  1. Liposomes
  2. Virosomes
  3. Gene gun
  4. Electroporation
  5. Others
7. Middle East and Africa Neoantigen Cancer Vaccine Market, By Application
  1. Lung
  2. Melanoma
  3. Gastrointestinal
  4. Brain cancer
  5. Others
8. UAE
  1. UAE Neoantigen Cancer Vaccine Market, By Product
    1. Personalised neo-antigen vaccine
    2. Off-the-shelf neoantigen vaccine
  2. UAE Neoantigen Cancer Vaccine Market, By Neoantigen Type
    1. Synthetic Long Peptide
    2. Nucleic acid
    3. Dendritic cell
    4. Tumour cell
  3. UAE Neoantigen Cancer Vaccine Market, By Route of Administration
    1. Intravenous
    2. Intramuscular
    3. Transdermal
    4. Others
  4. UAE Neoantigen Cancer Vaccine Market, By Cell
    1. Autologous
    2. Allogenic
  5. UAE Neoantigen Cancer Vaccine Market, By Technology
    1. RNA Sequencing
    2. Whole Genome Sequencing
    3. HLA Typing
  6. UAE Neoantigen Cancer Vaccine Market, By Delivery Mechanism
    1. Liposomes
    2. Virosomes
    3. Gene gun
    4. Electroporation
    5. Others
  7. UAE Neoantigen Cancer Vaccine Market, By Application
    1. Lung
    2. Melanoma
    3. Gastrointestinal
    4. Brain cancer
    5. Others
9. Turkey
10. Saudi Arabia
11. South Africa
12. Egypt
13. Nigeria
14. Rest of MEA
LATAM
1. LATAM Neoantigen Cancer Vaccine Market, By Product
  1. Personalised neo-antigen vaccine
  2. Off-the-shelf neoantigen vaccine
2. LATAM Neoantigen Cancer Vaccine Market, By Neoantigen Type
  1. Synthetic Long Peptide
  2. Nucleic acid
  3. Dendritic cell
  4. Tumour cell
3. LATAM Neoantigen Cancer Vaccine Market, By Route of Administration
  1. Intravenous
  2. Intramuscular
  3. Transdermal
  4. Others
4. LATAM Neoantigen Cancer Vaccine Market, By Cell
  1. Autologous
  2. Allogenic
5. LATAM Neoantigen Cancer Vaccine Market, By Technology
  1. RNA Sequencing
  2. Whole Genome Sequencing
  3. HLA Typing
6. LATAM Neoantigen Cancer Vaccine Market, By Delivery Mechanism
  1. Liposomes
  2. Virosomes
  3. Gene gun
  4. Electroporation
  5. Others
7. LATAM Neoantigen Cancer Vaccine Market, By Application
  1. Lung
  2. Melanoma
  3. Gastrointestinal
  4. Brain cancer
  5. Others
8. Brazil
  1. Brazil Neoantigen Cancer Vaccine Market, By Product
    1. Personalised neo-antigen vaccine
    2. Off-the-shelf neoantigen vaccine
  2. Brazil Neoantigen Cancer Vaccine Market, By Neoantigen Type
    1. Synthetic Long Peptide
    2. Nucleic acid
    3. Dendritic cell
    4. Tumour cell
  3. Brazil Neoantigen Cancer Vaccine Market, By Route of Administration
    1. Intravenous
    2. Intramuscular
    3. Transdermal
    4. Others
  4. Brazil Neoantigen Cancer Vaccine Market, By Cell
    1. Autologous
    2. Allogenic
  5. Brazil Neoantigen Cancer Vaccine Market, By Technology
    1. RNA Sequencing
    2. Whole Genome Sequencing
    3. HLA Typing
  6. Brazil Neoantigen Cancer Vaccine Market, By Delivery Mechanism
    1. Liposomes
    2. Virosomes
    3. Gene gun
    4. Electroporation
    5. Others
  7. Brazil Neoantigen Cancer Vaccine Market, By Application
    1. Lung
    2. Melanoma
    3. Gastrointestinal
    4. Brain cancer
    5. Others
9. Mexico
10. Argentina
11. Chile
12. Colombia
13. Rest of LATAM